We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse.
Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome.
The median OSM in biochemical responders was 86 (69-148) pg/mL compared with 166 (74-1766) pg/mL in nonresponders (
Elevated preinfliximab plasma OSM and nCD64 surface expression were both associated with poor biochemical outcomes.